UNASSIGNED: Several hundred Releaf App™ users from the state of Florida provided anonymous, real-time reports of their symptoms of anxiety and/or depression immediately before and after cannabis use sessions. Linear mixed-effects modeling was used to analyze the data at the symptom and user level.
UNASSIGNED: Results showed that for the majority of users, cannabis use was associated with a significant decrease in depression and anxiety symptomatology. While symptom type, doses per session, consumption method, and CBD levels were significant predictors of relief change, their effect sizes were small and should be interpreted with caution. At the user level, those who had positive relief outcomes in anxiety reported more doses and sessions, and those in the depression group reported more sessions.
UNASSIGNED: Our results generally support the therapeutic effectiveness of cannabis against depression/anxiety symptomatology. Future work should include standardized statistics and effect size estimates for a better understanding of each variable\'s practical contribution to this area of study.
■来自佛罗里达州的数百名ReleafApp™用户提供了匿名服务,在使用大麻之前和之后立即实时报告他们的焦虑和/或抑郁症状。线性混合效应模型用于分析症状和用户级别的数据。
■结果显示,对于大多数用户来说,使用大麻与抑郁和焦虑症状的显着减少有关。而症状类型,每个疗程的剂量,消耗方法,和CBD水平是救济变化的重要预测因素,它们的效应大小很小,应谨慎解释.在用户层面,那些在焦虑中有积极缓解结果的人报告了更多的剂量和疗程,抑郁症组的人报告了更多的疗程。
■我们的研究结果总体上支持大麻对抑郁/焦虑症状的治疗效果。未来的工作应包括标准化统计和效应大小估计,以便更好地了解每个变量对这一研究领域的实际贡献。